Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.
Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, Alumkal JJ, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T. Omlin A, et al. Among authors: alumkal jj. Invest New Drugs. 2015 Jun;33(3):679-90. doi: 10.1007/s10637-015-0235-5. Epub 2015 Apr 30. Invest New Drugs. 2015. PMID: 25920479 Clinical Trial.
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ; SU2C/PCF West Coast Prostate Cancer Dream Team; Maher CA, Feng FY, Quigley DA. Zhang M, et al. Among authors: alumkal jj. Nat Cell Biol. 2024 Jul;26(7):1176-1186. doi: 10.1038/s41556-024-01438-3. Epub 2024 Jun 13. Nat Cell Biol. 2024. PMID: 38871824
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. Lundberg A, et al. Among authors: alumkal jj. Cancer Res. 2023 Aug 15;83(16):2763-2774. doi: 10.1158/0008-5472.CAN-23-0593. Cancer Res. 2023. PMID: 37289025 Free PMC article.
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A 3rd, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, Alumkal JJ. Kumaraswamy A, et al. Among authors: alumkal jj. JCI Insight. 2023 Aug 8;8(15):e167440. doi: 10.1172/jci.insight.167440. JCI Insight. 2023. PMID: 37440313 Free PMC article.
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ. Hussain M, et al. Among authors: alumkal jj. Invest New Drugs. 2014 Oct;32(5):904-12. doi: 10.1007/s10637-014-0099-0. Epub 2014 Apr 26. Invest New Drugs. 2014. PMID: 24764124 Free PMC article. Clinical Trial.
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Bryce AH, et al. Among authors: alumkal jj. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227. doi: 10.1038/pcan.2016.71. Epub 2017 Jan 24. Prostate Cancer Prostatic Dis. 2017. PMID: 28117385 Free PMC article.
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung D, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Alumkal JJ, et al. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3. Clin Genitourin Cancer. 2017. PMID: 28344102 Clinical Trial.
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Rathkopf DE, et al. Among authors: alumkal jj. Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283. Ann Oncol. 2017. PMID: 28633425 Free PMC article. Clinical Trial.
109 results